Takeda TSE 4502NYSETAK today presented favorable interim results from a global pivotal Phase 3 randomized controlled openlabel crossover trial evaluating the safety and efficacy of TAK755 recombinant ADAMTS13 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura cTTP and pharmacokinetics PK characteristics of TAK755 as well as longterm data on TAK755 prophylaxis from a Phase 3b continuation study.
OTTAWA Early results from a federal byelection show the Tories cruising towards victory in a race that pitted Pierre Poilievre's Conservatives against Maxime Bernier's People's Party of Canada. As of about 12:40 a.m.